Research programme: monoclonal antibody HUI 77-derived cancer therapies - Micromet

Drug Profile

Research programme: monoclonal antibody HUI 77-derived cancer therapies - Micromet

Alternative Names: QH2B

Latest Information Update: 18 Mar 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Southern California
  • Developer Micromet Inc
  • Class Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Collagen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Eye disorders; Solid tumours

Most Recent Events

  • 05 May 2006 CancerVax Corporation merged with Micromet AG to form Micromet Inc
  • 03 Apr 2006 The US FDA has approved an IND application for D93 to begin phase I trials in solid tumours
  • 25 Jul 2005 Preclinical trials in Eye disorders in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top